

REVIEW ARTICLE

Dysregulated epigenetic modifications in psoriasis

Chang Zeng¹ | Lam C. Tsoi^{1,2} | Johann E. Gudjonsson^{1,3} ¹Department of Dermatology, University of Michigan, Ann Arbor, MI, USA²Department of Computational Medicine and Bioinformatics and Department of Biostatistics, University of Michigan Medical School, Ann Arbor, MI, USA³A. Alfred Taubman Medical Research Institute, Ann Arbor, MI, USA**Correspondence**

Johann E. Gudjonsson, Department of Dermatology, University of Michigan, Ann Arbor, MI, USA.

Email: johanng@med.umich.edu

Abstract

The observed incidence of psoriasis has been gradually increasing over time (J Am Acad Dermatol, 03, 2009, 394), but the underlying pathogenic factors have remained unclear. Recent studies suggest the importance of epigenetic modification in the pathogenesis of psoriasis. Aberrant epigenetic patterns including changes in DNA methylation, histone modifications and non-coding RNA expression are observed in psoriatic skin. Reversing these epigenetic mechanisms has showed improvement in psoriatic phenotypes, making epigenetic therapy a potential avenue for psoriasis treatment. Here, we summarize relevant evidence for epigenetic dysregulation contributing to psoriasis susceptibility and pathogenesis, and the factors responsible for epigenetic modifications, providing directions for potential future clinical avenues.

KEYWORDS

DNA methylation, epigenetics, histone modification, non-coding RNA, psoriasis

1 | INTRODUCTION

Psoriasis is a chronic inflammatory autoimmune skin disorder that affects more than 8 million people in the United States.¹ Due to the nature of visible skin symptoms including the appearance of skin lesions, characterized by sharply demarcated red scaly plaques, pruritus, skin pain and often psoriatic arthritis, patients with psoriasis generally have decreased quality of life.^{2,3} However, the pathogenic mechanism of psoriasis remains incompletely elucidated and many of the currently available therapeutic approaches still have limited long-term effectiveness^{4,5} and substantial patient dissatisfaction.^{6,7} As a result, better understanding of the pathogenesis of psoriasis is needed in order to develop better treatment options.

Histological and immunological analyses have revealed that many of the clinical symptoms of psoriasis are related to abnormal epidermal hyperproliferation and differentiation, together with increased infiltration and activation of immune cells.^{8,9} Multiple factors, including genetic susceptibility¹⁰⁻¹² and environmental factors,¹³ contribute to development of psoriasis. Thus, a recent twin study showed that genetic factors may explain up to 68% of the variation in susceptibility, while non-shared environmental factors may explain the rest.¹⁴ Thus, epigenetic changes may play a critical

role in psoriasis development as it mediates the mechanisms for both genetic and environmental factors.^{12,15,16}

Epigenetic modifications are processes that alter genome activity around DNA without changing DNA sequences and are mitotically stable. Alteration of gene expression leads to the differential regulation of cell signalling pathways. Genetic changes, such as single nucleotide polymorphism and copy number variation, can affect transcript expression level and are enriched among factors associated with diseases.¹⁷ Recently, epigenetic mechanisms have been shown to regulate gene expression at both transcriptional and post-transcriptional levels^{18,19} and contribute to the pathogenesis of various diseases.²⁰⁻²² Importantly, similar to genetic alterations, if epigenetic modifications are present in germline cells, the modification can be passed to future generations,²³ making epigenetics target for some heritable diseases.²⁴

The major epigenetic processes include DNA methylation, histone post-translational modifications and non-coding RNAs (ncRNAs). DNA methylation²⁵ and histone modifications²⁶ modulate chromatin structure and are part of transcriptional regulation, while ncRNAs participate in post-transcriptional regulation.²⁷ The influence of non-hereditary epigenetic changes is best shown by monozygotic twin comparison, with about 4-fold increase in DNA

methylation and histone acetylation differences being observed in 50-year-old twins compared to 3-year-old twins.²⁸

In stark contrast to DNA abnormalities, epigenetic changes can be reversible. This nature of epigenetic processes allows for reprogramming of cellular processes,²⁹ making them feasible targets for therapeutics. Thus, many of the epigenetic machineries have been targeted and applied in cancer therapy,³⁰ and 6 epigenetic drugs have currently been approved by the food and drug administration (FDA) for clinical use.³¹

Here in this review, we summarize recent discoveries (Figure 1) regarding the mechanisms by which epigenetic factors contribute to the pathogenesis of psoriasis, the factors that drive epigenetic modifications, and discuss how epigenetic changes can be targeted therapeutically.

2 | EPIGENETIC ALTERATION IN PSORIASIS

2.1 | DNA methylation

DNA methylation is the best studied epigenetic mechanism. DNA methylation is involved in various essential biological processes such as genomic imprinting, X-chromosome inactivation and

silencing of repetitive DNA elements.³² Dysregulation of DNA methylation has been identified in a wide range of diseases including cancer,³³ inflammatory disorders³⁴ and neurological diseases.³⁵ In this process, methyltransferases recruit a methyl group to a cytosine or adenine residue at the 5th position on the pyrimidine ring within the CpG dinucleotide.³⁶ When DNA methylation occurs in the promoter or enhancer region of a gene, it leads to decreased binding of transcription factors that mediate or enhance gene transcriptional activity, leading to repression of gene transcription.³⁷ On the contrary, loss of DNA methylation, caused by DNA hydroxy-methylation and demethylation, in the promoter or enhancer region of a gene will lead to re-activation or increased gene expression.^{38,39}

Several whole-genome DNA methylation analyses have shown similar number of hypermethylated and hypomethylated differential methylated regions (DMRs) in whole skin biopsies from patients with psoriasis when compared to normal healthy controls,^{40,41} suggesting the existence of altered methylation mechanism in psoriatic skin. A closer look at these differentially methylated genes, such as *S100A9*, *SELENBP1* and *CARD14*, further reveals the relationship of DNA methylation and pathologic features in psoriasis.⁴²




FIGURE 1 Epigenetic regulations in psoriasis. DNA methylation, histone modifications and non-coding RNAs are the 3 major mechanisms that regulate epigenomic profiles in psoriatic immune cells and keratinocytes. (A) DNA methyltransferases (DMNTs) are upregulated, while methylcytosine dioxygenases TET1/2 are downregulated in psoriatic cells, leading to change of DNA methylation level in regulatory elements in genes that are important for proliferation, apoptosis and immune responses. (B) Histone methylation and acetylation regulated by histone methyltransferases (EZH2), demethylases (Jmjd3) and deacetylases (HDAC1). These changes lead to alteration of expressions of genes related to epidermal proliferation and Th17 differentiation. (C) Non-coding RNAs (ncRNAs), including microRNA (miRNA), circular RNA (circRNA) and long non-coding RNA (lncRNA), are found differentially expressed in psoriatic cells. These ncRNAs may influence gene expression by interacting with each other, binding to transcription factors and mRNA. (D) Microbiota, stress, diet and smoking are some of the common factors that may contribute to epigenetic changes in psoriatic cells

DNA methylation can also serve as a biomarker for effective psoriasis treatment. Thus, comparison between psoriatic skin prior to and after 1 month of successful anti-TNF treatment (with >75% improvement in PASI score) showed that after TNF inhibitor treatment, methylation status of several methylated loci became more similar to uninvolved skin.⁴¹

In addition, recent studies have identified several male-specific differential methylated sites in psoriatic skin, which regulate genes that are tightly associated with psoriasis.⁴³ This may provide insights into the mechanisms why psoriasis severity tends to be greater in males.⁴⁴

As keratinocytes and immune cells are both playing important roles in the pathogenesis of psoriasis, reports of dysregulated DNA methylome in these cell types suggest their contribution to altered biological processes related to psoriasis.

2.2 | Abnormal regulation of DNA methylation in keratinocytes

2.2.1 | Hypermethylation

In the epidermis of skin, where 90% of cells are keratinocytes, hypermethylation has been identified in the promoter area of the *p16INK4a* gene in 30% of patients of psoriasis.⁴⁵ This leads to decreased expression of *p16INK4a*, which is negatively related to disease severity (as measured by Psoriasis Area and Severity Index (PASI)). *p16INK4a* is also a tumor suppressor, and its suppression has been demonstrated to promote cell proliferation⁴⁶ providing a plausible explanation how hypermethylation relates to increased PASI score.

2.2.2 | Hypomethylation

Hypomethylation was identified in 12 CpG sites from epidermal differentiation complex in psoriatic skin and correlates with enhanced expression of several psoriatic signature genes (including *OAS2*, *S100A7* and *S100A12*).⁴¹ Decreased methylation has also been shown in the intragenic area of *CYP2S1* in psoriatic keratinocytes.⁴⁷ Further studies have revealed that these methylation loci overlap with the enhancer region of *CYP2S1*, leading to change of *CYP2S1* expression affecting proliferation and immune response in keratinocytes.⁴⁸

2.2.3 | DNMT dysregulation

DNA methyltransferases (DNMTs) are important for the maintenance of DNA methylation in cells. Keratinocytes express *DNMT1*, *DNMT3A* and *DNMT3B*.⁴⁹ Under physiological conditions, *DNMT1* is important for maintaining epidermal progenitor cell function and suppression of epidermal differentiation.^{49,50} Recent study has shown that inhibition of *DNMT1* activity, using indirubin, suppresses

WIF1 promoter hypermethylation, leading to inhibition of proliferation and induction of apoptosis in keratinocytes.⁵¹ This also provides additional mechanism by which indirubin alleviates psoriasis-like skin phenotype in the IMQ-induced murine model.⁵²

2.2.4 | Hydroxyl-methylation

Another group of enzymes that is important for altered DNA methylation profiles in cells is the ten-eleven translocation (TET) dioxygenase family. TET enzymes cause DNA hydroxy-methylation by converting 5-methylcytosine to 5-hydroxymethylcytosine (5-hmC). The 5-hmC modification leads to recruitment of a different set of binding factors than 5-methylcytosine.⁵³ In the psoriatic epidermis, and the IMQ-induced mouse model, decreased expression of *TET1* and *TET2* is observed together with loss of 5-hmC modifications in several genes related to stem cell homeostasis regulations.⁵⁴ The loss of 5-hmC leads to accumulation of nestin which contributes to the formation of psoriasis epidermal architecture.^{54,55} In addition, in vitro modelling suggests that *TET2* may regulate inflammatory response in keratinocytes through modulation of expression levels of pro-inflammatory cytokines and chemokines.⁵⁶

2.3 | Abnormal regulation of DNA methylation in immune cells

In psoriasis, abnormal DNA methylation has been identified in peripheral blood mononuclear cells (PBMCs). Thus, PBMCs obtained from psoriatic patients showed global DNA methylation changes, most likely related to the increased *DNMT1* activity and decreased *MBD2* and *MeCP2* mRNA level in psoriatic PBMCs.⁵⁷ Naïve psoriatic CD4⁺ T cells also show distinct methylation profile compared to healthy controls or patients with atopic dermatitis.⁵⁸ These differential methylated sites were found to coincide with histone modifications and transcription factor binding sites, suggesting an active influence on gene transcription regulation. Combinatory analysis of methylation and transcriptome profiles of CD4⁺ and CD8⁺ T cells from monozygotic twins discordant for psoriasis showed effect on multiple immune response-related genes such as *IL13*, *TNFSF11*, *PTPN6*, *CCL5*, *NFATC1* and *PRF1*.^{59,60} Furthermore, in peripheral blood from psoriasis patients, *FOXP3* gene methylation was significantly higher in Tregs from patients with psoriasis compared to Tregs derived from normal healthy controls.⁶¹ The hypermethylation may lead to decreased *FOXP3* expression and reduction in the number of Treg cells resulting in unrestrained autoimmune responses.

2.4 | Histone modification

In eukaryotic cells, octamer of histones is wrapped with 147 bp of DNA into nucleosome, which is the fundamental subunit of

chromatin. As a result, the alteration of histone influences the nucleosome positioning and unwrapping characteristics, which changes the accessibility of DNA sequences near the nucleosome region.⁶² The histone octamer is composed of two copies of the four core histones: H2A, H2B, H3 and H4. Post-translational modifications (PTMs) on these histones, including methylation, acetylation, phosphorylation, ubiquitylation and ADP-ribosylation, have been shown to alter histone-DNA and histone-histone interactions, which then changes the transcription activity.⁶² In skin, several histone modifications have been described and implicated in the pathogenesis of psoriasis. Here, we summarized some of the more recent discoveries.

2.4.1 | Histone methylation

Histone methylation is normally observed on the side chains of lysine and arginine, and multiple methyl groups could be added to the histones: mono-, di- and tri-methylation are all observed.⁶³ Different than DNA methylation, histone methylation can result in either an active or repressed status of transcriptional activity. The result of histone methylation is based on both methylation site and number of methyl groups added.

Histone methylation is important in regulating cytokine production and drug responses in psoriasis. A recent study showed that H3K9me2 is important in modifying IL-23 expression in keratinocytes, and keratinocyte-derived IL-23 is sufficient to drive psoriatic phenotype in a psoriasis murine model.⁶⁴ Increased H3K4 methylation has been identified in PBMCs from psoriasis patients compared to controls, potentially contributing to differentially expressed genes in PBMCs.⁶⁵ Interestingly, following treatment with biologics, H3K4 and H3K27 methylation level differs significantly between drug responder and non-responder,⁶⁵ supporting a role of histone methylation marks as potential biomarkers for treatment response.

In psoriasis epidermis, histone H3K27me3 modification and enhancer of zeste homolog 2 (EZH2), a histone H3K27 methylase, are both upregulated.⁶⁶ Pharmacological and genetic inhibition of EZH2 leads to downregulation of H3K27me3, suppresses epidermal proliferation and ameliorates psoriatic phenotype in mouse model.⁶⁶ However, it still remains unclear whether this protective effect is achieved by H3K27me3 downregulation given that EZH2 can also act as a methyltransferase on non-histone targets such as *STAT3*.⁶⁷

Histone H3K27me3 modifications are also important for Th17 differentiation. Th17 cells play a pathogenic role in psoriasis, and inhibition of IL-17 signalling frequently leads to marked clinical improvement.⁶⁸ Overexpression of the H3K27me3 demethylase *Jmjd3* leads to reduced H3K27me3 levels and promotes Th17 cell differentiation.⁶⁹ Further studies are needed to determine the role of *Jmjd3* in the pathogenesis of psoriasis.

2.4.2 | Histone acetylation

Histone acetylation typically occurs on the lysine side chain of the N-terminal tail histone proteins. The addition of acetyl group

neutralized the positive charge of lysine and results in weaker interactions between histone and DNA leading to open chromatin and facilitation of active transcription.

Reduced level of acetylation in H3 and H4 has been observed in psoriatic PBMCs, with H4 acetylation levels correlating negatively with disease severity (as measured by PASI).^{65,70} One of the mechanisms that may link altered histone acetylation in immune cells with psoriasis development involves GLS1-mediated glutaminolysis.⁷¹ In this paper, GLS1 was shown to promote Th17 and $\gamma\delta$ T17 differentiation through enhancement of H3K9Ac and H3K27Ac in the *IL17A* promoter region.⁷¹

Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are two major groups of enzymes that are responsible for histone acetylation. HDAC-1 has been shown to be upregulated in psoriatic skin.^{72,73} Previous studies have shown that HDAC inhibition regulates Treg function⁷⁴ by increasing *Foxp3* expression⁷⁵ and preventing production of IL-17A.⁷⁶ As Treg plays an important role in the pathogenesis of psoriasis,⁷⁷ HDAC may be important for immune regulation in psoriasis. Moreover, HDAC has been shown to suppress expression of inflammatory genes in both macrophages and keratinocytes.⁷⁸ Another histone deacetylase, Sirtuin-1 (SIRT1), may also have a role in psoriasis pathogenesis. SIRT1 is regulated by TNF- α and is decreased in psoriatic skin.^{73,79} Several studies have shown that SIRT1 activation can induce anti-inflammatory⁸⁰ and apoptotic⁸¹ effects in keratinocytes. However, histone substrates of SIRT1 that may contribute to the psoriatic phenotype are yet to be identified.

Recently, inhibition of BET proteins, readers of histone acetylation, has been shown to suppress IMQ-induced psoriatic phenotypes in mice.⁸² This study showed that BET inhibition decreases the expression of RORC, IL-17A and IL-22, which are all important pro-inflammatory factors in psoriasis. This further indicates the importance of histone acetylation in the pathogenesis of psoriasis.

2.5 | Non-coding RNA

Non-coding RNAs (ncRNAs) are RNAs that are not translated into protein. Some of the major groups of ncRNAs are microRNA (miRNA), long non-coding RNA (lncRNA) and circular RNA (circRNA). These non-coding RNAs are known to perform their role through interacting with RNA, DNA and proteins, leading to changes of their structure and ultimately alteration of gene expression.^{83,84}

2.5.1 | MicroRNA

MicroRNAs are single-stranded, small non-protein-coding, endogenous RNAs. miRNAs regulate gene expression primarily by binding to the 3' UTR of mRNA, forming miRNA-mRNA complex and leading to degradation of mRNA. Depending on the binding partners, miRNAs can regulate various cellular processes. Aside

from interacting with mRNA, miRNAs are able to modulate gene expression by influencing epigenetic modifications. miRNAs are able to produce mitotically heritable gene silencing and may contribute to human diseases by modulating DNA methylation in CpG island.⁸⁵ In addition, miRNAs are showed to target enzymes that are important for DNA methylation^{86,87} and histone modifications.^{88,89} Together, these suggest important roles of miRNAs in epigenetic processes.

miRNA125b is one of the most downregulated miRNAs in lesional psoriatic skin. *In vitro* studies have shown that increased expression of miRNA125b suppresses keratinocyte proliferation and promotes differentiation. miRNA125b has been shown to regulate expression and translation of fibroblast growth factor receptor 2 (FGFR2)⁹⁰ and ubiquitin-specific peptidase 2 (USP2) in keratinocytes.⁹¹ A recent study further suggested that miRNA125b can mediate keratinocyte proliferation through suppression of BRD4 expression, thus influencing Jagged-1/Notch signalling pathway.⁹²

miR-200c is elevated in plasma and lesional skin from psoriasis patients compared to normal healthy control. More importantly, miR-200c levels are positively correlated with disease severity in psoriasis.⁹³ One of the confirmed targets of miR-200c is SIRT1,⁹⁴ a histone deacetylase influencing inflammatory and proliferation process in psoriasis, as mentioned before. Furthermore, circulating miR-200c in psoriasis is positively correlated with cardiovascular risk.⁹³

microRNAs may also regulate the function of T cells. microRNA-210 (miR-210) is highly expressed in psoriatic CD4+ T cells and psoriatic skin.⁹⁵ The inhibition of miR-210, through both pharmacological and genetic methods, results in amelioration of psoriasis-like symptoms in a mouse model, suggesting the crucial role of miR-210 in modulating immune responses.⁹⁵ An *in vitro* study further demonstrated that small extracellular vesicles, derived from psoriatic keratinocytes, have an increased expression of miR-381-3p.⁹⁶ The increased miR-381-3p was shown to target several genes including *UBR5*, *FOXO1* and *RORC2*, and influencing the polarization of Th1 and Th17 cells.

Aside from those mentioned above, multiple other miRNAs have been found to influence keratinocyte function in psoriasis. MiR-125b-5p,⁹⁷ miR-181-5p,⁹⁷ miR-187,⁹⁸ miR-145-5p,⁹⁹ miR-320b,¹⁰⁰ miR-20a-3p,¹⁰¹ miR-876-5p,¹⁰² miR-99a,¹⁰³ miR-4516,¹⁰⁴ miR-330,¹⁰⁵ let-7b,¹⁰⁶ miR-155,¹⁰⁷ miR-194¹⁰⁸ and miR-138¹⁰⁹ are downregulated in psoriatic keratinocytes. miR-223,¹¹⁰ miR-744-3p,¹¹¹ miR-31,¹¹² miR-126,¹¹³ miR-17-92¹¹⁴ and miR-146¹¹⁵ are upregulated in lesional psoriatic skin. In addition, upregulation of miR-31¹¹⁶ and miR-155¹¹⁷ has been shown to affect expression of inflammatory mediators in psoriatic skin. Let-7b downregulation is related to increased T-cell proliferation and IFN-g secretion through STAT3 targeting.¹¹⁸

2.5.2 | Long non-coding RNA

lncRNAs are non-protein-coding RNAs that are longer than 200 nt. lncRNAs act as epigenetic modulators through recruitment of

transcription factors and chromatin modifying proteins to transcriptionally active loci.¹¹⁹

Microarray studies have identified around 2200 lncRNAs that are dysregulated in psoriatic skin.¹¹⁹ Another study using RNA-seq identified over 4,000 differentially expressed lncRNAs in psoriatic skin compared to non-lesional and healthy skin.¹²⁰ Further co-expression analysis showed that differentially expressed lncRNAs are involved in immune related functions and epidermal differentiation.

One of the highly upregulated lncRNAs in psoriasis is lncRNA-RP6-65G23.1. By altering the expression of Bcl-xl, Bcl2 and influencing ERK1/2-AKT signalling pathway, RP6-65G23.1 was shown to promote keratinocyte proliferation and suppression of apoptosis.¹²¹ Similarly, lncRNA MIR31HG is upregulated in psoriatic lesions and influences keratinocyte proliferation through G2/M cell cycle arrest.¹²² In addition, lncRNA-MSX2P1 is upregulated in IL-22-treated keratinocytes and induces increased cell proliferation and expression of S100A7 through suppression of miR-6731-5p.¹²³

Psoriasis susceptibility-related RNA gene induced by stress (*PRINS*) is another important lncRNA that has been implicated in the pathogenesis of psoriasis. Thus, *PRINS* is upregulated in both lesional and non-lesional psoriatic skin.¹²⁴ It can induce the expression of the anti-apoptotic protein G1P3 in psoriatic keratinocytes, thus promoting cell proliferation.¹²⁵

Another lncRNA is the maternally expressed gene 3 (*MEG3*), which is downregulated in psoriatic skin, potentially due to the exposure of TNF- α .¹²⁶ *MEG3* binds to miR-21 and influences proliferation of skin keratinocytes through the inhibiting effect of miR-21 towards caspase-8.¹²⁶

2.5.3 | Circular RNA

Circular RNAs are long non-coding RNAs that are covalently linked on the 5' and 3' termini. As circRNAs contain binding motifs for several miRNAs and proteins, they are able to influence biological processes through binding to miRNA and proteins.¹²⁷

Transcriptome analysis demonstrated that circRNAs are less abundant in psoriatic skin compared to non-lesional and healthy skin.¹²⁸ The circRNAs, ciRS-7 and circZRNAB1, are identified as promising psoriasis diagnostic biomarkers. ciRS-7 inhibits miR-7 activity through binding.¹²⁹ As miR-7 is known to negatively regulate genes that are involved in cell growth,¹³⁰ its inhibitor ciRS-7 may contribute to the increased cell proliferation in psoriasis. However, further functional studies are needed to validate the circular RNAs in psoriasis pathogenesis.

3 | ENVIRONMENTAL FACTORS THAT CONTRIBUTE TO THE EPIGENETIC CHANGES IN PSORIASIS

Environmental factors are believed to be important drivers of psoriasis pathogenesis.¹³¹ They are also considered to be a major

promoter of epigenetic modifications that lead to transgenerational inheritance and phenotypic variation in human diseases. Here, we summarized how some of the environmental factors may contribute to psoriasis symptoms through epigenetic modifications.

3.1 | Microbiota

The skin microbiome population in psoriatic skin differs markedly compared to healthy skin.¹³² Activated immune responses, and high expression of various antimicrobial proteins, lead to dysbiosis resulting in reduced population of bacteria such as *Corynebacterium* spp.¹³³ Interestingly, gut microbiota is also altered in patients with psoriasis.¹³⁴ Using antibiotic that target Gram-positive bacteria in IMQ-induced psoriatic murine model led to decreased IL-17- and IL-22-producing T cells,¹³⁵ suggesting the importance of microbiota in influencing inflammatory processes central to psoriasis pathogenesis.

Several epigenetic modifiers are strongly influenced by microbiome and their metabolites. For example, short-chain fatty acids secreted by gut bacteria are able to inhibit HDAC activities.¹³⁶ Another example is that depletion of gut microbiome leads to changes in the methylation of the *TLR4* gene.¹³⁷ In addition, different microbiota result in different expression signature of miRNA in mice.¹³⁷ Together, these findings suggest the importance of endogenous bacteria in modifying epigenome in cells. However, not much information is available regarding whether skin microbiota directly changes the epigenetic profile in skin, and how different microbiota may contribute to psoriasis pathogenesis. Further research is needed to address this.

3.2 | Diet

Epidemiology studies have found that different diets influence treatment response in psoriasis. Low calorie and fish oil diet have shown to lead to improvement in disease activity.¹³⁸ One of the ways diet may alter epigenetic profile is through dietary intake and the effect of dietary metabolites in influencing microbiota composition.¹³⁹ Another way is through direct influence on epigenetic modifying enzymes. Several dietary components, such as butyrate, sulphoraphane, curcumin, resveratrol and genistein, are able to change the activity of HDAC, HAT and DNMTs.¹⁴⁰ Fish oil that contains omega-3 polyunsaturated fatty acids has been shown to affect DNA methylation profile.^{141,142}

3.3 | Smoking

Cigarette smoking has been shown to contribute to the onset of psoriasis, disease severity, response to treatment and increasing incidence of various psoriasis-associated comorbidities.¹⁴³ A genome-wide DNA methylation study suggested that, when comparing

current smokers with never smokers, that there were 18,760 differentially methylated CpG sites in relation to 7,201 annotated genes.¹⁴⁴ Smoking may also influence histone modifications by decreasing the activity of HDAC¹⁴⁵ and increasing histone methylation.¹⁴⁶ In addition, smoking influences epigenetic modifications through altering the expression of miRNAs¹⁴⁷ and lncRNAs.¹⁴⁸

Cigarette and cannabis smoking have been shown to lead to hypermethylation of two CpGs located in *GPR15* and *AHRR* genes in helper T cells, leading to increased number of GPR15⁺CD3⁺CD4⁺ cells in peripheral blood, a well-known marker for autoimmune diseases, including psoriasis.¹⁴⁹

3.4 | Stress

Epidemiology study suggested that stress contributes to both onset and exacerbation of psoriasis.^{150,151} Experiments using IMQ-induced psoriasis-like mouse model found that emotional stress induces higher expression of pro-inflammatory cytokines and resulted in more severe epidermal hyperplasia.¹⁵² Furthermore, other studies have shown that, when under stress, patients with psoriasis experience decreased level of cortisol.¹⁵³ Aside from its anti-inflammatory effect, cortisol induces epigenetic modifications including DNA methylation,¹⁵⁴⁻¹⁵⁶ histone modifications¹⁵⁷ and miRNA expression.¹⁵⁸ Although no studies have been done to determine whether stress causes epigenetic changes in psoriatic skin, the altered cortisol level¹⁵⁹ and its relationship with epigenetic changes suggest a potential role of stress in contributing to the epigenomic profile in psoriasis.

4 | EPIGENETIC THERAPY

The concept that epigenetic factors play an important role in the pathogenesis of psoriasis is emerging, and increasing effort has been put into targeting epigenetic modifiers. For example, 5-azacytidine (5-Za) has been used as inhibitor of DNA methylation.¹⁶⁰ Topical application of 5-Za on mouse model shows amelioration of IMQ-induced epidermal thickening, suggesting a potential therapeutic use of methylation inhibitor on psoriasis.¹⁶¹ Histone acetylation and deacetylation enzymes are another popular target in psoriasis treatment. HDAC inhibitor piperlongumine has been shown to alleviate IMQ-induced skin inflammation and keratinocyte hyperproliferation,⁷⁸ while another inhibitor trichostatin A has been shown to prevent T-cell differentiation towards pathogenic Th17 polarization.¹⁶² Furthermore, clinical trial using SIRT1 activator in treating psoriasis demonstrated significant histological improvement.¹⁶³

Several studies have also shown that alteration of non-coding RNA can be effective in treating psoriasis. Topical treatment of miR-210 inhibitor showed decreased acanthosis and inflammatory infiltration in IMQ-induced psoriasis.¹⁶⁴ Interestingly, treatment using ultrasound to target Q-starch and miR-197 resulted in significant improvement in psoriatic histology.¹⁶⁵

5 | CONCLUSION

Emerging importance of epigenetic regulation has been established in the pathogenesis of psoriasis. The specific epigenetic regulations in psoriasis can provide new targets for treatment development and serve as potential biomarker for diagnosis and treatment response.¹⁶⁶ However, greater understandings of epigenetic modifications in psoriasis are needed. For example, many of the current epigenetic studies have been performed in *in vitro* models that only contain a single cell type, but more complex models are required to fully assess the effectiveness of epigenetic therapies. Combinatorial therapies that utilize epigenetic targeting approaches together with standard psoriasis treatment should be also explored. As medications that target epigenetic modulators are rapidly being implemented in other diseases, a deeper understanding of the epigenetic mechanism involved in psoriasis pathogenesis will accelerate and facilitate the future use of epigenetic modifiers in psoriasis management.

ACKNOWLEDGEMENT

None.

CONFLICT OF INTEREST

The authors certify that they have no conflicts to declare in relation to the topic.

AUTHOR CONTRIBUTION

CZ, LCT and JEG wrote the paper.

ORCID

Johann E. Gudjonsson  <https://orcid.org/0000-0002-0080-0812>

REFERENCES

- Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. *J Am Acad Dermatol*. 2014;70(3):512-516.
- Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. *Health Qual Life Outcomes*. 2006;4:35.
- Augustin M, Radtke MA. Quality of life in psoriasis patients. *Expert Rev Pharmacoecon Outcomes Res*. 2014;14(4):559-568.
- Rendon A, Schakel K. Psoriasis pathogenesis and treatment. *Int J Mol Sci*. 2019;20(6):1475.
- Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. *Sci Rep*. 2018;8(1):16068.
- Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. *J Investig Dermatol Symp Proc*. 2004;9(2):136-139.
- Finch T, Shim TN, Roberts L, Johnson O. Treatment satisfaction among patients with moderate-to-severe psoriasis. *J Clin Aesthet Dermatol*. 2015;8(4):26-30.
- Albanesi C, Madonna S, Gisondi P, Girolomoni G. The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis. *Front Immunol*. 2018;9:1549.
- Benhadou F, Mintoff D, Del Marmol V. Psoriasis: keratinocytes or immune cells - which is the trigger? *Dermatology*. 2019;235(2):91-100.
- Smith RL, Warren RB, Griffiths CE, Worthington J. Genetic susceptibility to psoriasis: an emerging picture. *Genome Med*. 2009;1(7):72.
- Mahil SK, Capon F, Barker JN. Genetics of psoriasis. *Dermatol Clin*. 2015;33(1):1-11.
- Tsoi LC, Stuart PE, Tian C, et al. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. *Nat Commun*. 2017;8:15382.
- Dika E, Bardazzi F, Balestri R, Maibach HI. Environmental factors and psoriasis. *Curr Probl Dermatol*. 2007;35:118-135.
- Lonnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF. Heritability of psoriasis in a large twin sample. *Br J Dermatol*. 2013;169(2):412-416.
- Ho SM, Johnson A, Tarapore P, Janakiram V, Zhang X, Leung YK. Environmental epigenetics and its implication on disease risk and health outcomes. *ILAR J*. 2012;53(3-4):289-305.
- Aguilera O, Fernandez AF, Munoz A, Fraga MF. Epigenetics and environment: a complex relationship. *J Appl Physiol*. 2010;109(1):243-251.
- Jackson M, Marks L, May GHW, Wilson JB. The genetic basis of disease. *Essays Biochem*. 2018;62(5):643-723.
- Gibney ER, Nolan CM. Epigenetics and gene expression. *Heredity (Edinb)*. 2010;105(1):4-13.
- Fojtova M, Van Houdt H, Depicker A, Kovarik A. Epigenetic switch from posttranscriptional to transcriptional silencing is correlated with promoter hypermethylation. *Plant Physiol*. 2003;133(3):1240-1250.
- Stocco A, Coppede F. Role of epigenetics in Alzheimer's disease pathogenesis. *Neurodegener Dis Manag*. 2018;8(3):181-193.
- Zhang Z, Zhang R. Epigenetics in autoimmune diseases: Pathogenesis and prospects for therapy. *Autoimmun Rev*. 2015;14(10):854-863.
- Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. *Cancers (Basel)*. 2013;5(2):676-713.
- Skinner MK. Environmental stress and epigenetic transgenerational inheritance. *BMC Med*. 2014;12:153.
- Bohacek J, Mansuy IM. Epigenetic inheritance of disease and disease risk. *Neuropsychopharmacology*. 2013;38(1):220-236.
- Robertson KD. DNA methylation and chromatin - unraveling the tangled web. *Oncogene*. 2002;21(35):5361-5379.
- Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. *Cell Res*. 2011;21(3):381-395.
- Dykes IM, Emanuelli C. Transcriptional and Post-transcriptional Gene Regulation by Long Non-coding RNA. *Genom Proteom Bioinform*. 2017;15(3):177-186.
- Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. *Proc Natl Acad Sci USA*. 2005;102(30):10604-10609.
- Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. *Science*. 2013;339(6127):1567-1570.
- Ahuja N, Sharma AR, Baylin SB. Epigenetic therapeutics: a new weapon in the war against cancer. *Annu Rev Med*. 2016;67:73-89.
- Cheng Y, He C, Wang M, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. *Signal Transduct Target Ther*. 2019;4:62.
- Li E. Chromatin modification and epigenetic reprogramming in mammalian development. *Nat Rev Genet*. 2002;3(9):662-673.
- Gopalakrishnan S, Van Emburgh BO, Robertson KD. DNA methylation in development and human disease. *Mutat Res*. 2008;647(1-2):30-38.
- Bayarsaihan D. Epigenetic mechanisms in inflammation. *J Dent Res*. 2011;90(1):9-17.
- Weng YL, An R, Shin J, Song H, Ming GL. DNA modifications and neurological disorders. *Neurotherapeutics*. 2013;10(4):556-567.
- Feng S, Jacobsen SE, Reik W. Epigenetic reprogramming in plant and animal development. *Science*. 2010;330(6004):622-627.

37. Moore LD, Le T, Fan G. DNA methylation and its basic function. *Neuropsychopharmacology*. 2013;38(1):23-38.
38. Ichiyama K, Chen T, Wang X, et al. The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells. *Immunity*. 2015;42(4):613-626.
39. Bhutani N, Burns DM, Blau HM. DNA demethylation dynamics. *Cell*. 2011;146(6):866-872.
40. Zhang P, Zhao M, Liang G, et al. Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris. *J Autoimmun*. 2013;41:17-24.
41. Roberson ED, Liu Y, Ryan C, et al. A subset of methylated CpG sites differentiate psoriatic from normal skin. *J Invest Dermatol*. 2012;132(3 Pt 1):583-592.
42. Chandra A, Senapati S, Roy S, Chatterjee G, Chatterjee R. Epigenome-wide DNA methylation regulates cardinal pathological features of psoriasis. *Clin Epigenetics*. 2018;10(1):108.
43. Llamas-Velasco M, Reolid A, Sanz-García A, et al. Methylation in psoriasis. Does sex matter? *J Eur Acad Dermatol Venereol*. 2020;35:161-163.
44. Hagg D, Sundstrom A, Eriksson M, Schmitt-Egenolf M. Severity of Psoriasis differs between men and women: a study of the clinical outcome measure psoriasis area and severity index (pasi) in 5438 Swedish register patients. *Am J Clin Dermatol*. 2017;18(4):583-590.
45. Chen M, Chen ZQ, Cui PG, et al. The methylation pattern of p16INK4a gene promoter in psoriatic epidermis and its clinical significance. *Br J Dermatol*. 2008;158(5):987-993.
46. Jiang M, Lu W, Ding X, Liu X, Guo Z, Wu X. p16INK4a inhibits the proliferation of osteosarcoma cells through regulating the miR-146b-5p/TRAF6 pathway. *Biosci Rep*. 2019;39(2):268.
47. Zhou F, Wang W, Shen C, et al. Epigenome-wide association analysis identified nine skin DNA methylation loci for psoriasis. *J Invest Dermatol*. 2016;136(4):779-787.
48. Sheng Y, Wen L, Zheng X, et al. CYP2S1 might regulate proliferation and immune response of keratinocyte in psoriasis. *Epigenetics*. 2020;12:11.
49. Rinaldi L, Datta D, Serrat J, et al. Dnmt3a and Dnmt3b associate with enhancers to regulate human epidermal stem cell homeostasis. *Cell Stem Cell*. 2016;19(4):491-501.
50. Sen GL, Reuter JA, Webster DE, Zhu L, Khavari PA. DNMT1 maintains progenitor function in self-renewing somatic tissue. *Nature*. 2010;463(7280):563-567.
51. Liu SG, Luo GP, Qu YB, Chen YF. Indirubin inhibits Wnt/beta-catenin signal pathway via promoter demethylation of WIF-1. *BMC Complement Med Ther*. 2020;20(1):250.
52. Xie XJ, Di TT, Wang Y, et al. Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing gammadelta T cells. *Mol Immunol*. 2018;101:386-395.
53. Gustafson CB, Yang C, Dickson KM, et al. Epigenetic reprogramming of melanoma cells by vitamin C treatment. *Clin Epigenetics*. 2015;7:51.
54. Li F, Yuan CW, Xu S, et al. Loss of the epigenetic mark 5-hmC in psoriasis: implications for epidermal stem cell dysregulation. *J Invest Dermatol*. 2020;140(6):1266-1275.
55. Gomes CB, Zechin KG, Xu S, et al. TET2 negatively regulates nestin expression in human melanoma. *Am J Pathol*. 2016;186(6):1427-1434.
56. Liu X, Wang X, Liu N, et al. TET2 is involved in DNA hydroxymethylation, cell proliferation and inflammatory response in keratinocytes. *Mol Med Rep*. 2020;21(4):1941-1949.
57. Zhang P, Su Y, Chen H, Zhao M, Lu Q. Abnormal DNA methylation in skin lesions and PBMCs of patients with psoriasis vulgaris. *J Dermatol Sci*. 2010;60(1):40-42.
58. Han J, Park SG, Bae JB, et al. The characteristics of genome-wide DNA methylation in naive CD4+ T cells of patients with psoriasis or atopic dermatitis. *Biochem Biophys Res Commun*. 2012;422(1):157-163.
59. Li X, Zhao X, Xing J, et al. Different epigenome regulation and transcriptome expression of CD4(+) and CD8(+) T cells from monozygotic twins discordant for psoriasis. *Australas J Dermatol*. 2020;61:e388-e394.
60. Gervin K, Vigeland MD, Mattingsdal M, et al. DNA methylation and gene expression changes in monozygotic twins discordant for psoriasis: identification of epigenetically dysregulated genes. *PLoS Genet*. 2012;8(1):e1002454.
61. Ngalamika O, Liang G, Zhao M, et al. Peripheral whole blood FOXP3 TSDR methylation: a potential marker in severity assessment of autoimmune diseases and chronic infections. *Immunol Invest*. 2015;44(2):126-136.
62. Bowman GD, Poirier MG. Post-translational modifications of histones that influence nucleosome dynamics. *Chem Rev*. 2015;115(6):2274-2295.
63. Ng SS, Yue WW, Oppermann U, Klose RJ. Dynamic protein methylation in chromatin biology. *Cell Mol Life Sci*. 2009;66(3):407-422.
64. Li H, Yao Q, Mariscal AG, et al. Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation. *Nat Commun*. 2018;9(1):1420.
65. Ovejero-Benito MC, Reolid A, Sanchez-Jimenez P, et al. Histone modifications associated with biological drug response in moderate-to-severe psoriasis. *Exp Dermatol*. 2018;27(12):1361-1371.
66. Zhang T, Yang L, Ke Y, et al. EZH2-dependent epigenetic modulation of histone H3 lysine-27 contributes to psoriasis by promoting keratinocyte proliferation. *Cell Death Dis*. 2020;11(10):826.
67. Muller A, Dickmanns A, Resch C, et al. The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis. *J Clin Invest*. 2020;130(11):5765-5781.
68. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. *J Allergy Clin Immunol*. 2017;140(3):645-653.
69. Liu Z, Cao W, Xu L, et al. The histone H3 lysine-27 demethylase Jmjd3 plays a critical role in specific regulation of Th17 cell differentiation. *J Mol Cell Biol*. 2015;7(6):505-516.
70. Zhang P, Su Y, Zhao M, Huang W, Lu Q. Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris. *Eur J Dermatol*. 2011;21(4):552-557.
71. Xia X, Cao G, Sun G, et al. GLS1-mediated glutaminolysis unbridled by MALT1 protease promotes psoriasis pathogenesis. *J Clin Invest*. 2020;130(10):5180-5196.
72. Tovar-Castillo LE, Cancino-Diaz JC, Garcia-Vazquez F, et al. Under-expression of VHL and over-expression of HDAC-1, HIF-1alpha, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis. *Int J Dermatol*. 2007;46(3):239-246.
73. Hwang YJ, Na JI, Byun SY, et al. Histone deacetylase 1 and sirtuin 1 expression in psoriatic skin: a comparison between guttate and plaque psoriasis. *Life (Basel)*. 2020;10(9):157.
74. von Knethen A, Heinicke U, Weigert A, Zacharowski K, Brune B. Histone deacetylation inhibitors as modulators of regulatory T cells. *Int J Mol Sci*. 2020;21(7):2356.
75. Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. *Nat Med*. 2007;13(11):1299-1307.
76. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. *Blood*. 2008;112(6):2340-2352.
77. Nussbaum L, Chen YL, Ogg GS. Role of regulatory T cells in psoriasis pathogenesis and treatment. *Br J Dermatol*. 2020;184(1):14-24.
78. Thatikonda S, Pooladanda V, Sigalapalli DK, Godugu C. Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation. *Cell Death Dis*. 2020;11(1):21.

79. Fan X, Yan K, Meng Q, et al. Abnormal expression of SIRT1 in psoriasis: decreased expression of SIRT 1-5 and increased expression of SIRT 6 and 7. *Int J Mol Med*. 2019;44(1):157-171.
80. Lee JH, Moon JH, Lee YJ, Park SY. SIRT1, a Class III histone deacetylase, regulates LPS-induced inflammation in human keratinocytes and mediates the anti-inflammatory effects of hinokitiol. *J Invest Dermatol*. 2017;137(6):1257-1266.
81. Lee JH, Kim JS, Park SY, Lee YJ. Resveratrol induces human keratinocyte damage via the activation of class III histone deacetylase, Sirt1. *Oncol Rep*. 2016;35(1):524-529.
82. Nadeem A, Al-Harbi NO, Al-Harbi MM, et al. Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation. *Pharmacol Res*. 2015;99:248-257.
83. Wei JW, Huang K, Yang C, Kang CS. Non-coding RNAs as regulators in epigenetics (Review). *Oncol Rep*. 2017;37(1):3-9.
84. Neve B, Jonckheere N, Vincent A, Van seuningen I. epigenetic regulation by lncRNAs: an overview focused on UCA1 in colorectal cancer. *Cancers (Basel)*. 2018;10(11).
85. Tufarelli C, Stanley JA, Garrick D, et al. Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. *Nat Genet*. 2003;34(2):157-165.
86. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. *Hepatology*. 2010;51(3):881-890.
87. Wang YS, Chou WW, Chen KC, Cheng HY, Lin RT, Juo SH. MicroRNA-152 mediates DNMT1-regulated DNA methylation in the estrogen receptor alpha gene. *PLoS One*. 2012;7(1):e30635.
88. Song J, Jin EH, Kim D, Kim KY, Chun CH, Jin EJ. MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis. *BBA Clin*. 2015;3:79-89.
89. Tuddenham L, Wheeler G, Ntounia-Fousara S, et al. The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. *FEBS Lett*. 2006;580(17):4214-4217.
90. Xu N, Brodin P, Wei T, et al. MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2. *J Invest Dermatol*. 2011;131(7):1521-1529.
91. Wei T, Folkersen L, Biskup E, et al. Ubiquitin-specific peptidase 2 as a potential link between microRNA-125b and psoriasis. *Br J Dermatol*. 2017;176(3):723-731.
92. Pan M, Huang Y, Zhu X, Lin X, Luo D. miR-125b-mediated regulation of cell proliferation through the Jagged-1/Notch signaling pathway by inhibiting BRD4 expression in psoriasis. *Mol Med Rep*. 2019;19(6):5227-5236.
93. Magenta A, D'Agostino M, Sileno S, et al. The oxidative stress-induced miR-200c is upregulated in psoriasis and correlates with disease severity and determinants of cardiovascular risk. *Oxid Med Cell Longev*. 2019;2019:8061901.
94. Carlomosti F, D'Agostino M, Beji S, et al. Oxidative stress-induced miR-200c disrupts the regulatory loop among SIRT1, FOXO1, and eNOS. *Antioxid Redox Signal*. 2017;27(6):328-344.
95. Wu R, Zeng J, Yuan J, et al. MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation. *J Clin Invest*. 2018;128(6):2551-2568.
96. Jiang M, Fang H, Dang E, et al. Small extracellular vesicles containing miR-381-3p from keratinocytes promote T Helper Type 1 and T Helper Type 17 polarization in psoriasis. *J Invest Dermatol*. 2020;141:563-574.
97. Zheng Y, Cai B, Li X, Li D, Yin G. MiR-125b-5p and miR-181b-5p inhibit keratinocyte proliferation in skin by targeting Akt3. *Eur J Pharmacol*. 2019;862:172659.
98. Tang L, He S, Zhu Y, et al. Downregulated miR-187 contributes to the keratinocytes hyperproliferation in psoriasis. *J Cell Physiol*. 2019;234(4):3661-3674.
99. Yan JJ, Qiao M, Li RH, Zhao XT, Wang XY, Sun Q. Downregulation of miR-145-5p contributes to hyperproliferation of keratinocytes and skin inflammation in psoriasis. *Br J Dermatol*. 2019;180(2):365-372.
100. Wang Y, Yu X, Wang L, Ma W, Sun Q. miR-320b is down-regulated in psoriasis and modulates keratinocyte proliferation by targeting AKT3. *Inflammation*. 2018;41(6):2160-2170.
101. Li R, Qiao M, Zhao X, Yan J, Wang X, Sun Q. MiR-20a-3p regulates TGF-beta1/Survivin pathway to affect keratinocytes proliferation and apoptosis by targeting SFMBT1 in vitro. *Cell Signal*. 2018;49:95-104.
102. Rongna A, Yu P, Hao S, Li Y. MiR-876-5p suppresses cell proliferation by targeting Angiopoietin-1 in the psoriasis. *Biomed Pharmacother*. 2018;103:1163-1169.
103. Shen H, Tian Y, Yao X, Liu W, Zhang Y, Yang Z. MiR-99a inhibits keratinocyte proliferation by targeting Frizzled-5 (FZD5) / FZD8 through beta-catenin signaling in psoriasis. *Pharmazie*. 2017;72(8):461-467.
104. Chowdhari S, Sardana K, Saini N. miR-4516, a microRNA down-regulated in psoriasis inhibits keratinocyte motility by targeting fibronectin/integrin alpha9 signaling. *Biochim Biophys Acta Mol Basis Dis*. 2017;1863(12):3142-3152.
105. Shen H, Zeng B, Wang C, et al. MiR-330 inhibits IL-22-induced keratinocyte proliferation through targeting CTNBN1. *Biomed Pharmacother*. 2017;91:803-811.
106. Wu Y, Liu L, Bian C, et al. MicroRNA let-7b inhibits keratinocyte differentiation by targeting IL-6 mediated ERK signaling in psoriasis. *Cell Commun Signal*. 2018;16(1):58.
107. Xu L, Leng H, Shi X, Ji J, Fu J, Leng H. MiR-155 promotes cell proliferation and inhibits apoptosis by PTEN signaling pathway in the psoriasis. *Biomed Pharmacother*. 2017;90:524-530.
108. Yu X, An J, Hua Y, et al. MicroRNA-194 regulates keratinocyte proliferation and differentiation by targeting Grainyhead-like 2 in psoriasis. *Pathol Res Pract*. 2017;213(2):89-97.
109. Feng SJ, Chu RQ, Ma J, et al. MicroRNA138 regulates keratin 17 protein expression to affect HaCaT cell proliferation and apoptosis by targeting hTERT in psoriasis vulgaris. *Biomed Pharmacother*. 2017;85:169-176.
110. Wang R, Wang FF, Cao HW, Yang JY. MiR-223 regulates proliferation and apoptosis of IL-22-stimulated HaCat human keratinocyte cell lines via the PTEN/Akt pathway. *Life Sci*. 2019;230:28-34.
111. Wang C, Zong J, Li Y, Wang X, Du W, Li L. MiR-744-3p regulates keratinocyte proliferation and differentiation via targeting KLLN in psoriasis. *Exp Dermatol*. 2019;28(3):283-291.
112. Wang Q, Chang W, Yang X, et al. Levels of miR-31 and its target genes in dermal mesenchymal cells of patients with psoriasis. *Int J Dermatol*. 2019;58(2):198-204.
113. Feng S, Wang L, Liu W, Zhong Y, Xu S. MiR-126 correlates with increased disease severity and promotes keratinocytes proliferation and inflammation while suppresses cells' apoptosis in psoriasis. *J Clin Lab Anal*. 2018;32(9):e22588.
114. Zhang W, Yi X, An Y, et al. MicroRNA-17-92 cluster promotes the proliferation and the chemokine production of keratinocytes: implication for the pathogenesis of psoriasis. *Cell Death Dis*. 2018;9(5):567.
115. Hermann H, Runnel T, Aab A, et al. miR-146b probably assists miRNA-146a in the suppression of keratinocyte proliferation and inflammatory responses in psoriasis. *J Invest Dermatol*. 2017;137(9):1945-1954.
116. Xu N, Meisgen F, Butler LM, et al. MicroRNA-31 is overexpressed in psoriasis and modulates inflammatory cytokine and chemokine production in keratinocytes via targeting serine/threonine kinase 40. *J Immunol*. 2013;190(2):678-688.
117. Luo Q, Zeng J, Li W, et al. Silencing of miR155 suppresses inflammatory responses in psoriasis through inflammasome NLRP3 regulation. *Int J Mol Med*. 2018;42(2):1086-1095.
118. Hu XP, Xie Q, Chen CF, Zhang W, Yu B. Let-7a inhibits T-Cell proliferation and IFN-gamma secretion by down-regulating

- STAT3 expression in patients with psoriasis. *Cell Physiol Biochem*. 2017;42(1):115-125.
119. Mercer TR, Mattick JS. Structure and function of long non-coding RNAs in epigenetic regulation. *Nat Struct Mol Biol*. 2013;20(3):300-307.
 120. Tsoi LC, Iyer MK, Stuart PE, et al. Analysis of long non-coding RNAs highlights tissue-specific expression patterns and epigenetic profiles in normal and psoriatic skin. *Genome Biol*. 2015;16:24.
 121. Duan Q, Wang G, Wang M, et al. LncRNA RP6-65G23.1 accelerates proliferation and inhibits apoptosis via p-ERK1/2/p-AKT signaling pathway on keratinocytes. *J Cell Biochem*. 2020;121(11):4580-4589.
 122. Gao J, Chen F, Hua M, et al. Knockdown of lncRNA MIR31HG inhibits cell proliferation in human HaCaT keratinocytes. *Biol Res*. 2018;51(1):30.
 123. Qiao M, Li R, Zhao X, Yan J, Sun Q. Up-regulated lncRNA-MSX2P1 promotes the growth of IL-22-stimulated keratinocytes by inhibiting miR-6731-5p and activating S100A7. *Exp Cell Res*. 2018;363(2):243-254.
 124. Sonkoly E, Bata-Csorgo Z, Pivarcsi A, et al. Identification and characterization of a novel, psoriasis susceptibility-related noncoding RNA gene, PRINS. *J Biol Chem*. 2005;280(25):24159-24167.
 125. Szegedi K, Sonkoly E, Nagy N, et al. The anti-apoptotic protein G1P3 is overexpressed in psoriasis and regulated by the non-coding RNA, PRINS. *Exp Dermatol*. 2010;19(3):269-278.
 126. Jia HY, Zhang K, Lu WJ, Xu GW, Zhang JF, Tang ZL. LncRNA MEG3 influences the proliferation and apoptosis of psoriasis epidermal cells by targeting miR-21/caspase-8. *BMC Mol Cell Biol*. 2019;20(1):46.
 127. Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. *Nat Rev Genet*. 2019;20(11):675-691.
 128. Moldovan LI, Tsoi LC, Ranjitha U, et al. Characterization of circular RNA transcriptomes in psoriasis and atopic dermatitis reveals disease-specific expression profiles. *Exp Dermatol*. 2020;28:14227.
 129. Zheng XB, Zhang M, Xu MQ. Detection and characterization of ciRS-7: a potential promoter of the development of cancer. *Neoplasma*. 2017;64(3):321-328.
 130. Zhao J, Tao Y, Zhou Y, et al. MicroRNA-7: a promising new target in cancer therapy. *Cancer Cell Int*. 2015;15:103.
 131. Zeng J, Luo S, Huang Y, Lu Q. Critical role of environmental factors in the pathogenesis of psoriasis. *J Dermatol*. 2017;44(8):863-872.
 132. Hsu DK, Fung MA, Chen H-L. Role of skin and gut microbiota in the pathogenesis of psoriasis, an inflammatory skin disease. *Med Microecol*. 2020;4:100016.
 133. Fyhrquist N, Muirhead G, Prast-Nielsen S, et al. Microbe-host interplay in atopic dermatitis and psoriasis. *Nat Commun*. 2019;10(1):4703.
 134. Sikora M, Stec A, Chrabaszc M, et al. Gut microbiome in psoriasis: an updated review. *Pathogens*. 2020;9(6):463.
 135. Zanvit P, Konkel JE, Jiao X, et al. Antibiotics in neonatal life increase murine susceptibility to experimental psoriasis. *Nat Commun*. 2015;6:8424.
 136. Aoyama M, Kotani J, Usami M. Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways. *Nutrition*. 2010;26(6):653-661.
 137. Takahashi K, Sugi Y, Nakano K, et al. Epigenetic control of the host gene by commensal bacteria in large intestinal epithelial cells. *J Biol Chem*. 2011;286(41):35755-35762.
 138. Pona A, Haidari W, Kolli SS, Feldman SR. Diet and psoriasis. *Dermatol Online J*. 2019;25:2.
 139. Bhat MI, Kapila R. Dietary metabolites derived from gut microbiota: critical modulators of epigenetic changes in mammals. *Nutr Rev*. 2017;75(5):374-389.
 140. Remely M, Lovrecic L, de la Garza AL, et al. Therapeutic perspectives of epigenetically active nutrients. *Br J Pharmacol*. 2015;172(11):2756-2768.
 141. Fujii R, Yamada H, Munetsuna E, et al. Dietary fish and omega-3 polyunsaturated fatty acids are associated with leukocyte ABCA1 DNA methylation levels. *Nutrition*. 2021;81:110951.
 142. Karimi M, Vedin I, Freund Levi Y, et al. DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study. *Am J Clin Nutr*. 2017;106(4):1157-1165.
 143. Naldi L. Psoriasis and smoking: links and risks. *Psoriasis (Auckl)*. 2016;6:65-71.
 144. Joehanes R, Just AC, Marioni RE, et al. Epigenetic Signatures of Cigarette Smoking. *Circ Cardiovasc Genet*. 2016;9(5):436-447.
 145. Szulakowski P, Crowther AJ, Jimenez LA, et al. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2006;174(1):41-50.
 146. Sundar IK, Nevid MZ, Friedman AE, Rahman I. Cigarette smoke induces distinct histone modifications in lung cells: implications for the pathogenesis of COPD and lung cancer. *J Proteome Res*. 2014;13(2):982-996.
 147. Izzotti A, Larghero P, Longobardi M, et al. Dose-responsiveness and persistence of microRNA expression alterations induced by cigarette smoke in mouse lung. *Mutat Res*. 2011;717(1-2):9-16.
 148. Bi H, Zhou J, Wu D, et al. Microarray analysis of long non-coding RNAs in COPD lung tissue. *Inflamm Res*. 2015;64(2):119-126.
 149. Andersen AM, Lei MK, Beach SRH, Philibert RA, Sinha S, Colgan JD. Cigarette and cannabis smoking effects on GPR15+ helper T Cell levels in peripheral blood: relationships with epigenetic biomarkers. *Genes (Basel)*. 2020;11(2).
 150. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. *J Invest Dermatol*. 2005;125(1):61-67.
 151. Sathyanarayana Rao TS, Basavaraj KH, Das K. Psychosomatic paradigms in psoriasis: Psoriasis, stress and mental health. *Indian J Psychiatry*. 2013;55(4):313-315.
 152. Wang Y, Li P, Zhang L, et al. Stress aggravates and prolongs imiquimod-induced psoriasis-like epidermal hyperplasia and IL-1beta/IL-23p40 production. *J Leukoc Biol*. 2020;108(1):267-281.
 153. Evers AW, Verhoeven EW, Kraaimaat FW, et al. How stress gets under the skin: cortisol and stress reactivity in psoriasis. *Br J Dermatol*. 2010;163(5):986-991.
 154. Thomassin H, Flavin M, Espinas ML, Grange T. Glucocorticoid-induced DNA demethylation and gene memory during development. *EMBO J*. 2001;20(8):1974-1983.
 155. Bose R, Spulber S, Kilian P, et al. Tet3 mediates stable glucocorticoid-induced alterations in DNA methylation and Dnmt3a/Dkk1 expression in neural progenitors. *Cell Death Dis*. 2015;6:e1793.
 156. Yang X, Ewald ER, Huo Y, et al. Glucocorticoid-induced loss of DNA methylation in non-neuronal cells and potential involvement of DNMT1 in epigenetic regulation of Fkbp5. *Biochem Biophys Res Commun*. 2012;420(3):570-575.
 157. Vockley CM, D'Ippolito AM, McDowell IC, et al. Direct GR binding sites potentiate clusters of TF binding across the human genome. *Cell*. 2016;166(5):1269-1281 e1219.
 158. Dwivedi Y, Roy B, Lugli G, Rizavi H, Zhang H, Smalheiser NR. Chronic corticosterone-mediated dysregulation of microRNA network in prefrontal cortex of rats: relevance to depression pathophysiology. *Transl Psychiatry*. 2015;5:e682.
 159. Sarkar MK, Kaplan N, Tsoi LC, et al. Endogenous glucocorticoid deficiency in psoriasis promotes inflammation and abnormal differentiation. *J Invest Dermatol*. 2017;137(7):1474-1483.
 160. Jones PA, Taylor SM, Wilson VL. Inhibition of DNA methylation by 5-azacytidine. *Recent Results Cancer Res*. 1983;84:202-211.

161. Gao M, Si X. Rapamycin ameliorates psoriasis by regulating the expression and methylation levels of tropomyosin via ERK1/2 and mTOR pathways in vitro and in vivo. *Exp Dermatol*. 2018;27(10):1112-1119.
162. Soler DC, McCormick TS. The dark side of regulatory T cells in psoriasis. *J Invest Dermatol*. 2011;131(9):1785-1786.
163. Krueger JG, Suarez-Farinas M, Cueto I, et al. A randomized, placebo-controlled study of SRT2104, a SIRT1 activator, in patients with moderate to severe psoriasis. *PLoS One*. 2015;10(11):e0142081.
164. Feng H, Wu R, Zhang S, et al. Topical administration of nanocarrier miRNA-210 antisense ameliorates imiquimod-induced psoriasis-like dermatitis in mice. *J Dermatol*. 2020;47(2):147-154.
165. Lifshiz Zimon R, Lerman G, Elharrar E, et al. Ultrasound targeting of Q-starch/miR-197 complexes for topical treatment of psoriasis. *J Control Release*. 2018;284:103-111.
166. Ovejero-Benito MC, Cabaleiro T, Sanz-Garcia A, et al. Epigenetic biomarkers associated with antitumour necrosis factor drug response in moderate-to-severe psoriasis. *Br J Dermatol*. 2018;178(3):798-800.

How to cite this article: Zeng C, Tsoi LC, Gudjonsson JE. Dysregulated epigenetic modifications in psoriasis. *Exp Dermatol*. 2021;30:1156-1166. <https://doi.org/10.1111/exd.14332>